Trial reportHuman reproduction (Oxford, England)2026
Obstetric and perinatal outcomes from the follow-up of a multicentre randomized controlled trial investigating time-lapse embryo monitoring.
Trial report in Human reproduction (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost-effectiveness of time-lapse monitoring with or without the use of embryo selection software compared to routine incubation and selection.Human reproduction open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
study questionDoes uninterrupted culture in a time-lapse incubator with or without a commercially available machine learning embryo selection algorithm result in comparable obstetric and perinatal outcomes as interrupted culture and morphological embryo selection? SUMMARY ANSWER: The application of uninterrupted culture in a time-lapse incubator with and without the use of an embryo selection algorithm is comparable to interrupted embryo culture and morphological embryo selection in terms of obstetric and perinatal results. WHAT IS KNOWN ALREADY: There is very limited evidence regarding the safety of time-lapse monitoring (TLM) from prospective randomized controlled trials (RCT). Recent RCTs have demonstrated that the application of TLM does not increase (cumulative) live birth rates or shorten the time to pregnancy within 1 year. Although most studies only report pregnancy rates, the safety of this commonly used method is also relevant for decision-making. STUDY DESIGN, SIZE, DURATION: The obstetric and perinatal outcomes of patients scheduled for Day 3 single embryo transfer who participated in a multicentre RCT on TLM were studied (SelecTIMO trial). Three groups were compared: (i) TLE: embryo selection based on a commercially available Day 3 TLM algorithm, used adjunctively with morphology, and uninterrupted culture. (ii) TLR: routine morphological embryo selection and uninterrupted culture. (iii) CON: routine morphological embryo selection and interrupted culture. PARTICIPANTS/MATERIALS, SETTING,
methodsIn total, 1731 IVF/ICSI patients undergoing their first, second, or third oocyte retrieval cycle were randomized. Obstetric and perinatal data were registered for all pregnancies occurring after fresh and frozen embryo transfers associated with the initial oocyte retrieval cycle as well as natural conceptions within 1 year. Serious pregnancy complications and birth weight were considered main safety outcomes. Mean differences (MD) and age-adjusted relative risks (RRadj) and mean differences with 95% CI were calculated for TLE and TLR versus CON. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 827 women gave birth to a singleton during the follow-up period (TLE = 275, TLR = 278, CON = 274; P = 0.99). Of the 827 women who gave birth to a singleton, 497 deliveries originated from a fresh embryo transfer (60%), 294 from a frozen embryo transfer (36%), and 36 women conceived naturally (4%), with similar proportions in each study group. The proportion of women with serious pregnancy complications was comparable across the three groups (TLE vs CON: RRadj 0.95, 95% CI 0.65-1.40 and TLR vs CON: RRadj 1.03, 95% CI 0.70-1.50; P = 0.89). Mean (SD) gestational age at birth was 39.4 (1.9) weeks, 39.5 (1.5) weeks, and 39.3 (1.9) weeks, respectively. We found no evidence of differences in preterm and very preterm births between groups. Mean (SD) weight at birth was 3413 (588) g, 3412 (588) g, and 3377 (578) g, respectively (TLE vs CON: MD 34, 95% CI -62 to 129 and TLR vs CON: MD 32, 95% CI -635 to 120; P = 0.70). We did not observe substantial differences in babies with low and very low birth weight. Health problems immediately after delivery were reported for eight babies in the TLE group, 12 in the TLR group, and 11 in the CON group. Major congenital malformations occurred in four children in the TLE group, four in the TLR group, and seven in the CON group. Minor congenital malformations occurred in five children in the TLE group, three in the TLR group, and five in the CON group. LIMITATIONS, REASONS FOR CAUTION: This study reports safety outcomes for one type of time-lapse incubator, however, more systems are currently available. WIDER IMPLICATIONS OF THE
findingsOur results suggest that uninterrupted time-lapse culture with and without embryo selection based on machine learning can be regarded as safe compared to interrupted embryo culture and routine morphological selection in terms of obstetric and perinatal risks. STUDY FUNDING/COMPETING INTEREST(S): The authors received a grant from the Netherlands Organisation for Health Research and Development (ZonMw) for the execution of the SelecTIMO study (Health Care Efficiency Research programme grant 843001602). Merck (Germany and The Netherlands) supplied the six time-lapse incubators, funded the laboratory adjustments, and provided technical support and training to laboratory personnel before and during the study. D.C.K. received the Fertility Society of Australia exchange award. The following declarations of interest were made outside of the submitted work: F.B. reports additional financial support for the LUMO trial from Besins Healthcare Monaco, fellowship grants for ongoing basic research from Merck, consulting fees and payment or honoraria from Merck, Besins, and Ferring, and is member of the DSMB of the POISE study UK. J.M.J.S. has received grants or contracts from Ferring BV and Merck (payments to ETZ in both cases); consulting fees for an advisory board from Ferring BV; speakers fee from Merck BV; and support for conference attendance from Ferring BV, Merck, and Goodlife. M.v.W. is Senior Editor of Cochrane and Editor-in-Chief of Human Reproduction Update. C.B.L. reports a speakers honorarium from Organon (The Netherlands) and was Editor In Chief for Human Reproduction at the time of submitting this manuscript. TRIAL REGISTRATION NUMBER: NTR5423: ICTRP Search Portal (who.int).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.